Updated:
MED-FINE Capital
MED-FINE Capital is a healthcare-focused venture and growth investor operating from Shanghai across China's life sciences sector.
MED-FINE Capital
MED-FINE Capital is a Shanghai-headquartered private equity firm concentrating exclusively on the healthcare and life sciences sectors. The firm invests from seed through growth stages, drawing on what its public materials describe as a management team with deep roots in the pharmaceutical industry and venture investment. The firm's strategy spans early and expansion-stage venture, targeting drug development platforms, medical devices, and healthcare services. While specific portfolio companies are not publicly itemized on the firm's own website, its stated remit covers the full value chain of China's domestic health innovation economy — from drug discovery through clinical-stage biotech to scaled healthcare delivery. The firm operates across China. Details on fund sizes, aggregate capital deployed, and individual investment professionals are not publicly disclosed by the firm. Public records do not identify separate philanthropic vehicles or operating companies linked to MED-FINE Capital. The firm's structural edge rests on its sector concentration. By focusing solely on health and life sciences and sourcing deal flow from within China's research-hospital and biotech cluster ecosystems, it operates a model distinct from generalist technology or consumer-focused venture firms active in the same markets.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Sector focus
Frequently asked questions
What investment stages does MED-FINE Capital target?
The firm states it targets early-stage, seed, start-up, expansion, late-stage, and growth opportunities, all within healthcare and life sciences. This spans incubation-stage biotech platforms through to companies nearing commercialization.
Which sectors does MED-FINE Capital explicitly cover?
MED-FINE Capital is exclusively focused on healthcare and life sciences. Its website and public materials reference pharmaceutical, biotech, medical device, and healthcare service investments across China.
Where is MED-FINE Capital headquartered, and what is its geographic coverage?
The firm is headquartered in Shanghai, China, and its investment activities are stated to cover the broader China market. No additional international offices are publicly listed.
Who founded and leads MED-FINE Capital?
Specific principals are not named on the firm's public website or in widely available English-language sources. The firm describes its management team as having extensive pharmaceutical industry and venture capital experience.
Does MED-FINE Capital disclose its assets under management or fund sizes?
No. MED-FINE Capital has not publicly disclosed assets under management, aggregate deployment figures, or fund-level capitalizations in its currently available online materials.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: